Advertisement
U.S. markets closed

Invivyd, Inc. (IVVD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.4400+0.4400 (+11.00%)
At close: 04:00PM EDT
4.2800 -0.16 (-3.60%)
After hours: 05:35PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.0000
Open3.9700
Bid4.3900 x 200
Ask4.4700 x 200
Day's Range3.9600 - 4.5600
52 Week Range0.9800 - 5.1950
Volume1,496,680
Avg. Volume779,722
Market Cap527.676M
Beta (5Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-1.5500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IVVD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Invivyd, Inc.
    Daily – Vickers Top Insider Picks for 03/08/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

    Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise PEMGARDA product availability in the U.S. anticipated imminentlyPEMGARDA is the first authorized mAb from Invivyd’s INVYMAB™ platform approach designed to address the challenge of rapid viral evolutionLeveraged INVYMAB platform approach to design VYD2311, the company’s nex

  • GlobeNewswire

    Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

    Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development workToday’s update on Day 67 and Day 90 event rates is the first of two planned public updates on symptomatic COVID-19 events in CANOPY; Invivyd plans to analyze all future events at Day 180Further defining the relationship between serum virus neutralizing antibody titers and clinical protection that pro

  • GlobeNewswire

    Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

    Figure 1. Calculated sVNA titers against JN.1 based on observed pharmacokinetic concentration by timepoints (Cohort A) Figure 1 PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency use authorization based on positive immunobridging data and on safety data from the CANOPY clinical trial along with ongoing in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1PEMGARDA is